Editorial

Continue or discontinue warfarin for fecal occult blood testing in 2010? does the published evidence provide an answer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Whether to continue or discontinue warfarin before fecal occult blood testing (FOBT) requires comparison of the risks and benefits of both choices. Clinical practice varies on this issue, and guidelines are silent. A small body of evidence about the effect of warfarin on test characteristics of FOBT is inconclusive, although it suggests no effect. Retrospective studies on this topic may be prone to transfer bias, which affects the composition of the groups assembled for study. Considering the risks and benefits of discontinuing warfarin qualitatively, along with the published literature and clinical context in 2010, where tolerance for false-positive results is higher than it used to be and where immunochemical FOBT is a better screening test than older, guaiac-based FOBT, no seems like the commonsense answer.

Original languageEnglish
Pages (from-to)2036-2039
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume105
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Occult Blood
Warfarin
Guaiac
Retrospective Studies
Guidelines

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

@article{f350471a6d8d4d0b9ce74d8a02a0b291,
title = "Editorial: Continue or discontinue warfarin for fecal occult blood testing in 2010? does the published evidence provide an answer",
abstract = "Whether to continue or discontinue warfarin before fecal occult blood testing (FOBT) requires comparison of the risks and benefits of both choices. Clinical practice varies on this issue, and guidelines are silent. A small body of evidence about the effect of warfarin on test characteristics of FOBT is inconclusive, although it suggests no effect. Retrospective studies on this topic may be prone to transfer bias, which affects the composition of the groups assembled for study. Considering the risks and benefits of discontinuing warfarin qualitatively, along with the published literature and clinical context in 2010, where tolerance for false-positive results is higher than it used to be and where immunochemical FOBT is a better screening test than older, guaiac-based FOBT, no seems like the commonsense answer.",
author = "Thomas Imperiale",
year = "2010",
month = "9",
doi = "10.1038/ajg.2010.269",
language = "English",
volume = "105",
pages = "2036--2039",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Editorial

T2 - Continue or discontinue warfarin for fecal occult blood testing in 2010? does the published evidence provide an answer

AU - Imperiale, Thomas

PY - 2010/9

Y1 - 2010/9

N2 - Whether to continue or discontinue warfarin before fecal occult blood testing (FOBT) requires comparison of the risks and benefits of both choices. Clinical practice varies on this issue, and guidelines are silent. A small body of evidence about the effect of warfarin on test characteristics of FOBT is inconclusive, although it suggests no effect. Retrospective studies on this topic may be prone to transfer bias, which affects the composition of the groups assembled for study. Considering the risks and benefits of discontinuing warfarin qualitatively, along with the published literature and clinical context in 2010, where tolerance for false-positive results is higher than it used to be and where immunochemical FOBT is a better screening test than older, guaiac-based FOBT, no seems like the commonsense answer.

AB - Whether to continue or discontinue warfarin before fecal occult blood testing (FOBT) requires comparison of the risks and benefits of both choices. Clinical practice varies on this issue, and guidelines are silent. A small body of evidence about the effect of warfarin on test characteristics of FOBT is inconclusive, although it suggests no effect. Retrospective studies on this topic may be prone to transfer bias, which affects the composition of the groups assembled for study. Considering the risks and benefits of discontinuing warfarin qualitatively, along with the published literature and clinical context in 2010, where tolerance for false-positive results is higher than it used to be and where immunochemical FOBT is a better screening test than older, guaiac-based FOBT, no seems like the commonsense answer.

UR - http://www.scopus.com/inward/record.url?scp=77956299376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956299376&partnerID=8YFLogxK

U2 - 10.1038/ajg.2010.269

DO - 10.1038/ajg.2010.269

M3 - Article

VL - 105

SP - 2036

EP - 2039

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -